Tüdőrák: vizsgálatok itt: Kína
1144 trials · From ClinicalTrials.gov, checked 2026. november 16.. Ask the study team whether a trial fits you.
- 1/2. fázisTaking peopleInduction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 108
- Run by
- Shanghai Chest Hospital
See details and how to joinNCT07632365 - 1. fázisTaking peopleA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Where
- Beijing, Shanghai
- Életkor
- 18 év and over
- People
- 714 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00 - 1. fázisTaking peopleA Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- Where
- Guangzhou, Jinan, Shanghai
- Életkor
- 18 év and over
- People
- 914 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT06131840 · EU 2023-505858-18-00 - 1. fázisTaking peoplePhase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC
- Where
- Chengdu
- Életkor
- 18 év to 70 év
- People
- 30
- Run by
- Sichuan University
See details and how to joinNCT06348797 - 2. fázisTaking peopleA Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
- Where
- Cangzhou, Fu'zhou, Guangzhou, Harbin, Hefei, Nanning, Shanghai, Wuha, Xinxiang, Xuzhou
- Életkor
- 18 év to 75 év
- People
- 120
- Run by
- Shanghai Henlius Biotech
See details and how to joinNCT07253142 - 2. fázisNot yet taking people in KínaA Multicenter, Open-label, Randomized, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy
- Where
- Zhengzhou
- Életkor
- 18 év to 75 év
- People
- 200
- Run by
- Henan Cancer Hospital
See details and how to joinNCT07559786 - No phaseNot yet taking people in KínaJS212 in Combination With JS111 as First-Line Treatment in EGFR-Mutant Advanced NSCLC
- Where
- Hefei, Shanghai
- Életkor
- 18 év to 75 év
- People
- 20
- Run by
- Huan Zhou
See details and how to joinNCT07714304 - 2. fázisNot yet taking people in KínaA Phase 2 Study of ABSK043 Combined With Osimertinib
- Where
- Guangzhou, Hangzhou, Harbin, Shanghai, Shenyang, Taiyuan, Wuhan
- Életkor
- 18 év and over
- People
- 72
- Run by
- Abbisko Therapeutics Co, Ltd
See details and how to joinNCT07710612 - No phaseTaking peopleClinical Study of a New Treatment Model for Elderly Lung Cancer Patients
- Where
- Beijing
- Életkor
- 65 év and over
- People
- 1000
- Run by
- Peking University People's Hospital
See details and how to joinNCT07632664 - 2. fázisNot yet taking people in KínaThe Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer
- Where
- Shanghai
- Életkor
- 18 év to 70 év
- People
- 180
- Run by
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
See details and how to joinNCT07704645 - 3. fázisTaking peopleRC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
- Where
- Anyang, Baoding, Beijing, Binzhou, Cangzhou, Changchun, Changsha, Chengdu, Chongqing, Dongguan, Fuzhou, Guangzhou, Guilin, Guiyang, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nanyang, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Ürümqi, Wenzhou, Wuhan, Wuhu, Xiamen, Xi'an, Xiangyang, Xinxiang, Xuzhou, Yinchuan, Zhengzhou, Zhuhai, Zhuzhou
- Életkor
- 18 év to 75 év
- People
- 574
- Run by
- RemeGen Co., Ltd.
See details and how to joinNCT07416474 - 2. fázisTaking peopleA Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 348
- Run by
- Akeso
See details and how to joinNCT07669779 - Korai 1. fázisTaking peopleSafety and Preliminary Efficacy of [177Lu]Lu-RTX-2358 Combined With Immune Checkpoint Inhibitors in Patients With FAP-positive Metastatic Non-Small Cell Lung Cancer
- Where
- Wuhan
- Életkor
- 18 év and over
- People
- 36
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07689643 - 1. fázisNot yet taking people in KínaHSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 258
- Run by
- Haisco Pharmaceutical Group Co., Ltd.
See details and how to joinNCT07699757 - 1/2. fázisTaking peopleA Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC
- Where
- Hangzhou
- Életkor
- 18 év to 75 év
- People
- 116
- Run by
- Wuhan YZY Biopharma Co., Ltd.
See details and how to joinNCT05543330 - No phaseTaking peoplePrimary Tumor Resection for M1a Stage Lung Cancer
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 66
- Run by
- Fudan University
See details and how to joinNCT06547710 - 2. fázisTaking peopleFirmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma
- Where
- Changsha
- Életkor
- 18 év and over
- People
- 15
- Run by
- Hunan Cancer Hospital
See details and how to joinNCT07314216 - 1. fázisTaking peopleA Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC
- Where
- Beijing, Shanghai
- Életkor
- 18 év to 75 év
- People
- 138
- Run by
- Shanghai Henlius Biotech
See details and how to joinNCT07416695 - No phaseTaking peopleMulti-omics Study of Early-stage Lung Cancer With Distinct Phenotypes
- Where
- Changsha
- Életkor
- 18 év and over
- People
- 300
- Run by
- Central South University
See details and how to joinNCT06699979 - 2. fázisTaking peopleJS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 35
- Run by
- Shanghai Junshi Bioscience Co., Ltd.
See details and how to joinNCT07518160 - No phaseNot yet taking people in KínaA Non-interventional, Real-world Study on the Adjuvant Treatment of Chinese EGFR-positive Stage IA NSCLC Patients With High-risk Factors Using Third-generation EGFR-TKIs.
- Where
- Nanning
- Életkor
- 18 év and over
- People
- 500
- Run by
- First Affiliated Hospital of Guangxi Medical University
See details and how to joinNCT07686185 - 2. fázisTaking peopleA Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer
- Where
- Tianjin
- Életkor
- 18 év to 75 év
- People
- 25
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07358676 - 1/2. fázisTaking peopleA Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer
- Where
- Chengdu, Guangzhou, Harbin, Zhengzhou
- Életkor
- 18 év and over
- People
- 294 worldwide
- Run by
- Avistone Biotechnology Co., Ltd.
See details and how to joinNCT07538804 - 1. fázisTaking peoplePHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 396
- Run by
- Hansoh BioMedical R&D Company
See details and how to joinNCT07645222 - 1. fázisTaking peopleA Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
- Where
- Changchun, Changsha, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Luoyang, Nanchang, Shanghai, Shenyang, Wuhan
- Életkor
- 18 év and over
- People
- 214
- Run by
- Shanghai Junshi Bioscience Co., Ltd.
See details and how to joinNCT06839105